Emergency Filtration Products Reports Preliminary Results of New Nano Material Testing; Test of New Nano Material Against H9 N2 Avian Flu Strain Scheduled for Late April 2006
The testing was conducted at Nelson Laboratories in Salt Lake City. While additional testing needs to be conducted to confirm initial findings, this custom engineered nano material appeared to be highly effective in immediately arresting all three pathogens. The results of the additional tests will be published when completed.
“The results of tests undertaken at Nelson Laboratories, while still in the early stages, have been quite impressive against black spore mold, staph and herpes”
This material is scheduled to be tested against a strain of the avian flu H9 N2 at an East Coast-based medical testing laboratory later this month. Results from the H9 N2 testing are expected shortly thereafter.
"The results of tests undertaken at Nelson Laboratories, while still in the early stages, have been quite impressive against black spore mold, staph and herpes," said Douglas K. Beplate, president and CEO, EFP. "Additional testing will be needed to confirm the observations made to date. However, we are sufficiently confident in the results achieved so far that we have scheduled this nano material to be tested against H9 N2, an avian flu strain. Moreover, we look forward to testing this new nano material, as well as others that are currently under development, against H5 N1 as soon as possible."
About the NanoMask
EFP's 2H Nano-Enhanced Environmental Mask, the NanoMask, relies on the company's core 2H Technology(TM) filtration system, which utilizes a combination of hydrophobic and hydrophilic filters able to capture and isolate bacterial and viral microorganisms with efficiencies of 99.9%. The environmental mask utilizes the company's patented 2H Technology(TM) and nanotechnology to enhance the capture-and-isolation characteristics of the filter media.
About Emergency Filtration Products (http://www.emergencyfiltration.com/)
EFP is an air filtration products manufacturer whose patented 2H Technology(TM) filter system has produced filtration efficiencies of "greater than 99.99%" at a particulate size of 0.027 microns. Its initial products were developed for the medical market: the Vapor Isolation Valve(TM) and RespAide(R) CPR Isolation Mask used for resuscitation of respiratory/cardiac arrest cases; and the 2H Breathing Circuit Filter for ventilators, respirators and anesthesia circuitry. Each has received FDA approval. The company also markets an Automated External Defibrillator Prep Kit featuring RespAide; and the NanoMask(R), a nanotechnology enhanced environmental mask. In addition to filtration products, the company supplies Superstat(R), a modified hemostatic collagen, to the U.S. military for surgery and extreme wound care.
Safe Harbor Statement
This release may contain statements that are forward looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. Specifically, as stated above, the announced testing results are preliminary and will need to be confirmed by additional testing currently taking place. Regardless of the results of future tests, the company's sales may be dependent on the success of future marketing campaigns, the results of existing distribution agreements, and both the perceived need for EFP's products and the competitive performance of such products in the marketplace.